{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:52:02Z","timestamp":1761562322439},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1097\/hjh.0000000000001663","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T04:03:43Z","timestamp":1515038623000},"page":"979-986","source":"Crossref","is-referenced-by-count":7,"title":["SPRINT in context"],"prefix":"10.1097","volume":"36","author":[{"given":"Mattias","family":"Brunstr\u00f6m","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Carlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210208","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/S0140-6736(12)61766-8","article-title":"A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lim","year":"2012","journal-title":"Lancet"},{"key":"R2-3-20210208","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(14)61682-2","article-title":"Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.","volume":"385","year":"2015","journal-title":"Lancet"},{"key":"R3-3-20210208","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2016.19043","article-title":"Global burden of hypertension and systolic blood pressure of at least 110 to 115\u200amm Hg, 1990-2015","volume":"317","author":"Forouzanfar","year":"2017","journal-title":"JAMA"},{"key":"R4-3-20210208","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"R5-3-20210208","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/08037051.2015.1134086","article-title":"Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients","volume":"25","author":"Filipovsk\u00fd","year":"2016","journal-title":"Blood Press"},{"key":"R6-3-20210208","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1161\/HYPERTENSIONAHA.116.07257","article-title":"Unattended blood pressure measurements in the Systolic Blood Pressure Intervention Trial: implications for entry and achieved blood pressure values compared with other trials","volume":"67","author":"Kjeldsen","year":"2016","journal-title":"Hypertension"},{"key":"R8-3-20210208","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R9-3-20210208","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R10-3-20210208","first-page":"MR000033","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R11-3-20210208","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1177\/0962280211432211","article-title":"Reflections on meta-analyses involving trials stopped early for benefit: is there a problem and if so, what is it?","volume":"22","author":"Bassler","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"R12-3-20210208","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1161\/HYPERTENSIONAHA.115.06722","article-title":"SPRINT trial results: latest news in hypertension management","volume":"67","author":"Cushman","year":"2016","journal-title":"Hypertension"},{"key":"R13-3-20210208","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3109\/08037051.2015.1130775","article-title":"The SPRINT study: outcome may be driven by difference in diuretic treatment demasking heart failure and study design may support SBP target below 140 mmHg rather than below 120 mmHg","volume":"25","author":"Kjeldsen","year":"2016","journal-title":"Blood Press"},{"key":"R14-3-20210208","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"R15-3-20210208","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"R16-3-20210208","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney Int"},{"key":"R17-3-20210208","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"key":"R18-3-20210208","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","article-title":"Irbesartan in patients with atrial fibrillation","volume":"364","author":"Yusuf","year":"2011","journal-title":"N Engl J Med"},{"key":"R19-3-20210208","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"R20-3-20210208","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa065061","article-title":"Effect of ramipril on the incidence of diabetes","volume":"355","author":"Bosch","year":"2006","journal-title":"N Engl J Med"},{"key":"R21-3-20210208","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1056\/NEJMoa1600175","article-title":"Blood-pressure lowering in intermediate-risk persons without cardiovascular disease","volume":"374","author":"Lonn","year":"2016","journal-title":"N Engl J Med"},{"key":"R22-3-20210208","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting enzyme-inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"R23-3-20210208","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1001121","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","volume":"362","author":"McMurray","year":"2010","journal-title":"N Engl J Med"},{"key":"R24-3-20210208","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/HJH.0b013e3282ff8864","article-title":"The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure - a prospective, randomized, controlled prevention trial of the German Hypertension League","volume":"26","author":"Luders","year":"2008","journal-title":"J Hypertens"},{"key":"R25-3-20210208","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1161\/01.CIR.0000146378.65439.7A","article-title":"Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria","volume":"110","author":"Asselbergs","year":"2004","journal-title":"Circulation"},{"key":"R27-3-20210208","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"R28-3-20210208","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"R29-3-20210208","doi-asserted-by":"crossref","first-page":"982","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004","article-title":"Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus - a randomized, controlled trial","volume":"128","author":"Ravid","year":"1998","journal-title":"Ann Int Med"},{"key":"R30-3-20210208","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"R31-3-20210208","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1161\/HYPERTENSIONAHA.116.08216","article-title":"SPRINT blood pressure: sprinting back to Smirk's basal blood pressure?","volume":"69","author":"Parati","year":"2017","journal-title":"Hypertension"},{"key":"R33-3-20210208","doi-asserted-by":"crossref","first-page":"i717","DOI":"10.1136\/bmj.i717","article-title":"Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses","volume":"352","author":"Brunstr\u00f6m","year":"2016","journal-title":"BMJ"},{"key":"R34-3-20210208","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamainternmed.2017.6015","article-title":"Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis","volume":"178","author":"Brunstr\u00f6m","year":"2017","journal-title":"JAMA Intern Med"},{"key":"R35-3-20210208","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/HJH.0000000000001547","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J Hypertens"},{"key":"R36-3-20210208","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1097\/HJH.0000000000001548","article-title":"Effects of blood-pressure-lowering treatment on outcome incidence. 11. Effects of total cardiovascular risk and achieved blood pressure: overview and meta-analyses of randomized trials","volume":"35","author":"Thomopoulos","year":"2017","journal-title":"J Hypertens"},{"key":"R37-3-20210208","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1016\/S0140-6736(16)31326-5","article-title":"Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study","volume":"388","author":"Vidal-Petiot","year":"2016","journal-title":"Lancet"},{"key":"R38-3-20210208","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(17)30754-7","article-title":"Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials","volume":"389","author":"B\u00f6hm","year":"2017","journal-title":"Lancet"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0000000000001663","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:17:02Z","timestamp":1620955022000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201805000-00003"}},"subtitle":["meta-analysis of trials with baseline normotension and low levels of previous cardiovascular disease"],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0000000000001663","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}